Strategic consulting firm serving the life sciences industry, with operations across the US & Europe; Specialized expertise in oncology, CNS, & rare diseases
Joined December 2013
- Tweets745
- Following43
- Followers1.6K
- Likes29
BREAKING NEWS: Today we welcome Cognite, a scientific, medical, and commercial communications agency to the Blue Matter family. Learn more about it here >> bit.ly/4i9CeA3
#lifesciences #biopharma #sciencecommunications #bluematter #bringingsciencetolife
8 key themes from the #healthpolicy environment that will shape #oncology therapy access in 2027 >> bit.ly/4dSRXks
How to build a Best Practice launch organization (report from our latest study on launch organizational excellence) >> bit.ly/4ed9CmW
4 key themes from the recent Cell & Gene Meeting on the Mesa in Phoenix, AZ >> bit.ly/4s36GiA
We convened 18 sr #biopharma leaders in London to discuss the state of the UK #biotech industry. This group discussed a wide range of topics, including commercialization strategy, finance, people & talent, & program development. Read the synopsis here >> bit.ly/4jOY3WB
5 issues that biopharma companies must address regarding #psychedelic medicines >> bit.ly/4xWyMxm
eBook: 10 success factors for launching & commercializing cell / gene therapies >> bit.ly/4hIi2ox
5 key issues that #biopharma companies developing #psychedelic therapies will need to address if they are to succeed >> bit.ly/46KWSQf
#pharmaceuticals #biotech #CNSTherapies #CNS
Why an early start is critical when building the commercial infrastructure for a cell / gene therapy >> bit.ly/4zQP9O4
#celltherapy #genetherapy #oncology #rarediseases
The latest from our Policy team: The US is the global leader in #biopharma innovation, but will that position last? >> bit.ly/4qE2uoA
NEW >> How internal training & cross-functional coordination can make or break a cell / gene therapy >> bit.ly/4xhOEL5
#celltherapy #genetherapy #oncology #rarediseases
Is CMS asking biopharma companies for a number that doesn't exist?
The IRA has CMS weigh a drug's R&D costs & whether they've been recouped, but no manufacturer's accounting system produces a per-asset, lifetime figure.
Our take on the gap, and a fix: bit.ly/3SjSpjU
NEW >> Patient support services for cell / gene therapies & why traditional hub models often fall short >> bit.ly/4wxbnTi
#celltherapies #genetherapies #biotech #pharmaceuticals #patientsupport
NEW >> The patient experience & why proper engagement is so important with cell / gene therapies >> bit.ly/4wAqYkD
#celltherapy #genetherapy #biotech #pharmaceuticals #patientengagement #patientexperience
7 Key Themes from #ASCO26 >> bit.ly/3Qno3ME
#oncology #cancer #biotech #pharmaceuticals #cencerresearch #ASCO
Medical comms that get deployed to the field often become detached from the core strategy that initiated them. For #MedicalAffairs, that's a problem. Here's what to do about it >> bit.ly/4wY3Z3X
On May 13, Blue Matter hosted a roundtable discussion with 27 senior biopharma leaders in the Boston area. Now, you can read a summary of these open and insightful conversations: bit.ly/4agCp86
#biotech #pharmaceuticals #biopharma #BlueMatter
Our team recently attended the ISPOR 2026 meeting in Philadelphia. Here are 5 key themes they saw at the conference >> bit.ly/3S4pcZM
#HEOR #RWE #HealthEconomics #biotech #pharmaceuticals
How can you drive access & reimbursement success for a cell / gene therapy? This new article explains why CGT reimbursement is different from specialty pharma, & offers some key success factors for manufacturers. >> bit.ly/3RyMFCj
#biotech #pharmaceuticals #celltherapy
